Collaborations

Boehringer Ingelheim
Boehringer Ingelheim

2021, 01- Boehringer Ingelheim will develop a new Adeno-Associated Virus (AAV) vector for next-generation gene therapy through Cure Genetics' proprietary VELP platform. This collaboration combines Boehringer Ingelheim's experience in disease mechanism research and gene therapy development with Cure Genetics' expertise in viral library construction and efficient in vivo AAV screening, providing patients with potentially safer and more effective new AAV serotypes.

More

>
Frametact Limited
Frametact Limited

2023, 09- Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases. According to the agreement, Cure Genetics will receive an upfront and milestone payment totaling $60 million. Additionally, upon the market launch of the product, Cure Genetics will continue to receive sales royalties based on net revenue.
Frametact Limited was founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases. The company integrates profound research technologies in neurobiology, neuropharmacology, and neurodegenerative diseases, including Alzheimer's disease, Frametact’s mission is to leverage advanced neuroscience platforms to elevate the research and development of treatment products for neurological diseases.

More

>

Collaborations

Our core competencies include an experienced management team, proprietary and unique technology platforms, and an innovative differentiated product pipeline.
Our core competencies include an experienced management team, proprietary and unique technology platforms, and an innovative differentiated product pipeline.

In the area of external collaboration, we aim to establish long-term partnership relationships, striving to be the preferred partner for global enterprises and institutions. We actively seek partners for global development and commercialization of products.

We are actively looking for the following types of collaboration opportunities

01
Product Licensing/ Co-Development
Product Licensing/ Co-Development

Cure Genetics, based on its unique technology platform, has incubated several pioneering cell therapy pipelines. The first pipeline targeting clear cell renal cell carcinoma has shown safety and efficacy in clinical research and can be concurrently expanded to other autologous/allogeneic/in vivo pipelines. We are seeking global partners for external product licensing or collaborative development.

02
Platform Collaboration
Platform Collaboration

Our AAV vector development platform VELP, with its effective library diversity and low mis-packing rate, combined with DNA nuclear enrichment-RNA signal detection technology, has already completed multiple licensing collaborations. We are actively promoting the translation of gene therapy products targeting the nervous system, heart, and kidneys based on the platform. We are also actively seeking global partners for joint exploration based on gene therapy platforms.

03
In-License opportunities
In-License opportunities

We are open to introducing innovative clinical stage projects that have the potential to address unmet clinical needs, to expand our layout in cell and gene therapy pipelines for solid tumors and genetic diseases.

04
Early-stage Collaboration
Early-stage Collaboration

We maintain a continuous development attitude towards early scientific research and actively collaborate with research institutions, start-ups, and other organizations for early R&D.

For more information, please contact

BD@curegenectis.com